Abstract
A growing number of studies provide insight into how SARS-CoV-2 spreads1-7. Yet, many factors that characterize its transmissibility remain unclear, including mechanistic correlates of overdispersion, viral kinetics, the extent to which respiratory droplets and aerosols carry viable virus and the infectiousness of asymptomatic, presymptomatic and pediatric cases7. Here, we developed a comprehensive dataset of respiratory viral loads (rVLs) via systematic review and investigated these factors using meta-analyses and modeling. By comparing cases of COVID-19, SARS and influenza A(H1N1)pdm09, we found that heterogeneity in rVL was associated with overdispersion and facilitated the distinctions in individual variation in infectiousness among these emergent diseases. For COVID-19, case heterogeneity was broad throughout the infectious period, although rVL tended to peak at 1 day from symptom onset (DFSO) and be elevated for 1-5 DFSO. While most cases presented minimal risk, highly infectious ones could spread SARS-CoV-2 by talking, singing or breathing, which shed virions at comparable rates via droplets and aerosols. Coughing shed considerable quantities of virions, predominantly via droplets, and greatly increased the contagiousness of many symptomatic cases relative to asymptomatic ones. Asymptomatic and symptomatic infections showed similar likelihoods of expelling aerosols with SARS-CoV-2, as did adult and pediatric cases. Children tended to be less contagious by droplet spread than adults based on tendencies of symptomatology rather than rVL. Our findings address longstanding questions on SARS-CoV-2 transmissibility and present pertinent considerations for disease control.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Toronto COVID-19 Action Fund. P.Z.C. was supported by the NSERC Vanier Scholarship (608544). D.N.F. was supported by the Canadian Institutes of Health Research (Canadian COVID-19 Rapid Research Fund, OV4-170360). F.X.G. was supported by the NSERC Senior Industrial Research Chair.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
None required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be made available upon request. All raw data, code and model outputs from this study will be made publicly available in online repositories after peer review. Search strategies for the systematic review are shown in Supplementary Tables 1-5. The systematic review protocol was prospectively registered on PROSPERO (registration number, CRD42020204637).
